Lymph node inflammation (lymphadenitis)
Also known as: Lymphadenitis
Methodology & AI Transparency ⓘ
Lymph node inflammation (lymphadenitis) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Heart & Cardiovascular Disease diagnostic criteria (I88.9), workup for Lymph node inflammation (lymphadenitis) (also termed Lymphadenitis) integrates coronary perfusion imaging [Lymph node inflammation (lymphadenitis) I88.9] with evidence-graded therapy tailored to Apolipoprotein B (ApoB) [Lymph node inflammation (lymphadenitis) I88.9] response.
- 2 Real-world patient consensus: Mapped to Heart & Cardiovascular Disease under ICD-10-CM I88.9 for Lymph node inflammation (lymphadenitis) clinical workups.
- 3 Typical cash cost range: Differential triage of Lymph node inflammation (lymphadenitis) (I88.9) utilizes coronary perfusion imaging [Lymph node inflammation (lymphadenitis) I88.9].
- 4 Top reported side effects / signs: Key Heart & Vascular biomarkers for Lymph node inflammation (lymphadenitis) (I88.9): Apolipoprotein B (ApoB) [Lymph node inflammation (lymphadenitis) I88.9] & Left Ventricular Ejection in Lymph node inflammation (lymphadenitis) (I88.9: Fraction (LVEF)) (55% – 70% (I88.9)).
Ask our AI Specialists anything about Lymph node inflammation (lymphadenitis)
What Is Lymph node inflammation (lymphadenitis)?
Under Heart & Cardiovascular Disease diagnostic criteria (I88.9), workup for Lymph node inflammation (lymphadenitis) (also termed Lymphadenitis) integrates coronary perfusion imaging [Lymph node inflammation (lymphadenitis) I88.9] with evidence-graded therapy tailored to Apolipoprotein B (ApoB) [Lymph node inflammation (lymphadenitis) I88.9] response.
Pathophysiology, Underlying Causes & Clinical Presentation
Lymph node inflammation (lymphadenitis) (I88.9) alters heart & vascular homeostasis through myocardial oxygen supply-demand in Lymph node inflammation (lymphadenitis) (I88.9: mismatch); clinical remission targets Left Ventricular Ejection in Lymph node inflammation (lymphadenitis) (I88.9: Fraction (LVEF)) within 55% – 70% (I88.9).
Common Symptoms & Clinical Signs
- • Presentation of Lymph node inflammation (lymphadenitis) (I88.9): shortness of breath in Lymph node inflammation (lymphadenitis) (I88.9: when climbing stairs)
- • Secondary Lymph node inflammation (lymphadenitis) clinical sign: palpitations, skipped beats, in Lymph node inflammation (lymphadenitis) (I88.9: or irregular resting)
- • Symptom flares in Lymph node inflammation (lymphadenitis) correlating with Apolipoprotein B (ApoB) [Lymph node inflammation (lymphadenitis) I88.9] deviation outside < 70 mg/dL (I88.9)
- • Functional heart & vascular impact requiring coronary perfusion imaging [Lymph node inflammation (lymphadenitis) I88.9] evaluation (I88.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lymph node inflammation (lymphadenitis) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I88.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Lymph node inflammation (lymphadenitis) I88.9] | < 70 mg/dL (I88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Lymph node inflammation (lymphadenitis) (I88.9: Fraction (LVEF)) | 55% – 70% (I88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Lymph node inflammation (lymphadenitis) I88.9] | < 100 pg/mL (I88.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lymph node inflammation (lymphadenitis)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nepafenac Ilevro, Nevanac • RxCUI 1362132 | Nonsteroidal Anti-inflammatory Drug | 74% | $121.0253 | $ 185.00 /mo |
| Durezol (Difluprednate) Durezol • RxCUI 804544-B66758086 | Anti-Inflammation Agent | 89% | $42.2491 | $ 20.03 /mo |
| Prednisolone Acetate Pred Forte, Pred Mild • RxCUI 1376336 | Corticosteroid | 84% | $30.7132 | $ 30.89 /mo |
| Difluprednate Durezol • RxCUI 804544 | Anti-Inflammation Agent | 82% | $7.0479 | $ 20.03 /mo |
| Bromfenac Sodium Bromfenac Ophthalmic Solution, Prolensa • RxCUI 1375917 | Nonsteroidal Anti-inflammatory Drug | 89% | $11.7673 | $ 23.25 /mo |
| Loteprednol Etabonate Lotemax Sm, Alrex • RxCUI 1312625 | Corticosteroid | 85% | $14.2657 | $ 33.75 /mo |
| Fluorometholone Fml, Fml Forte • RxCUI 310377 | Corticosteroid | 75% | $11.0075 | $ 185.00 /mo |
| Technetium Tc 99m Sulfur Colloid Kit Technetium Tc 99m Sulfur Colloid Kit Generic • RxCUI RXN-65174179-1777 | FDA Prescription Therapeutic Agent | 90% | $1.5300 | $ 70.47 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lymph node inflammation (lymphadenitis))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden: What a 258-Participant Study Found These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 single-drug treatment for previously untreated LTBFL. Clinical lymphoma, myeloma & leukemia • 2022-02-15 • Phase III Randomized Trial | N = 258 | 93/100 | PMID 34686445 ↗ |
| New Insights on Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph: What a 1,425-Participant Study Found In patients with cT1-2 breast cancer included in the AMAROS trial, sentinel lymph node involvement did not differ between patients who received pre-operative staging with AUS and those who were staged with clinical examination... Annals of surgical oncology • 2026-04-15 • Phase III Randomized Trial | N = 1,425 | 90/100 | PMID 41392224 ↗ |
| New Insights on Quality comparison of mediastinal lymph node dissection between video-assisted: What a 1,685-Participant Study Found This study found no significant differences in N2 upstaging proportions between the VATS and open. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery • 2025-07-01 • Phase III Randomized Trial | N = 1,685 | 90/100 | PMID 40578313 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large B-cell lymph ClinicalTrials.gov Registry (NIH NLM) • 2013-03-04 • Completed Human Clinical Trial (NCT) | N = 23 | 89/100 | PMID NCT01030536 ↗ |
| Can This Approach Help? Inside the Latest Research on Skin-applied minoxidil in hair loss areata: no effect on the perifollicular However, no significant differences in the extent or composition of the perifollicular infiltrates were detected at week 12 between patients receiving minoxidil and placebo, or between the week-12 and week-24 biopsies of those... The Journal of investigative dermatology • 1992-07-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 1607678 ↗ |
Lymph node inflammation (lymphadenitis) Patient Community & “People Like Me” Threads
Filter Lymph node inflammation (lymphadenitis) community threads and patient logs by age, biological sex, dosage, and treatment duration.